Air Products & Chemicals, Inc. (APD) Stock Price Today
Aura AI Summary
Key Stats
- $70.49BMarket Cap
- 651,272Volume
- Basic MaterialsSector
- $318.8752W High
- $230.4252W Low
- 62 DaysTypical Hold Time
- $87.39BEnterprise Value
- 2.29%Div Yield
- 0% Sell | 100% BuyTrading Activity
Track Air Products & Chemicals, Inc. (APD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Air Products & Chemicals, Inc. has traded between a low of $230.42 and a high of $318.87, highlighting its annual price range. Buy and sell Air Products & Chemicals, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Most Recent News
Anthropic AI IPO set for Nov 19; analyst prefers Amazon stock over the new listing.
Anthropic, an AI company, is expected to go public with its IPO on November 19, 2026. However, analyst Daniel Sparks suggests that investors might be better off buying Amazon stock instead of Anthropic's IPO shares. This reflects skepticism about the...

Chery unveils integrated land, air, and parking system to transform travel efficiency and connectivity.
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem combining its Level 4 Robotaxi, Lingxiao eVTOL aircraft, and Super Intelligent Valet Parking (SIVP). This system aims to reduce travel transfers and overcome...

Liquidia retains PAH drug YUTREPIA rights post-settlement, limiting PH-ILD market but securing revenue.
Liquidia Corporation settled with United Therapeutics, keeping the rights to market YUTREPIA for pulmonary arterial hypertension (PAH) but losing some commercial potential in pulmonary hypertension associated with interstitial lung disease (PH-ILD). ...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.